[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100392697":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":114,"collaborators":10,"id":116,"slug":117,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":118,"sex":124,"minAge":125,"maxAge":10,"enrollmentInfo":126,"targetDuration":10,"studyType":129,"phases":10,"briefSummary":130,"conditions":131,"keywords":10,"overallStatus":38,"whyStopped":10,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":142},{"fullName":5,"class":6},"Acotec Scientific Co., Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"non-CLI group",null,"Rutherford Clinical Category (RCC) 2-3",[13],"Device: AcoArt Orchid (0.035\"), AcoArt Tulip (0.018\") and AcoArt Litos (0.014\") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.",{"label":15,"type":10,"description":16,"interventionNames":17},"CLI group","critical limb ischemia，Rutherford Clinical Category (RCC) 4-6",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"DEVICE","AcoArt Orchid (0.035\"), AcoArt Tulip (0.018\") and AcoArt Litos (0.014\") percutaneous transluminal angioplasty (PTA) paclitaxel drug coated balloon catheter manufactured by Acotec Scientific Co., Ltd.","All comers Post Market Clinical Follow-up to continue the surveillance of the Acotec Drug Coated PTA Catheter AcoArt Orchid, AcoArt Tulip and AcoArt Litos in lower limb treatment",[15,9],[25],{"name":26,"affiliation":27,"role":28},"Schmidt Andrej","Department of Angiology, University Hospital Leipzig","PRINCIPAL_INVESTIGATOR",[30],{"name":26,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","+49-341-97","18770","Andrej.Schmidt@medizin.uni-leipzig.de",[36,51,61,72,83,92,103],{"facility":37,"status":38,"city":37,"state":39,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Halle","RECRUITING","Saxony-Anhalt","Germany","DE",{"type":43,"coordinates":44},"Point",[45,46],11.97947,51.48158,{"lat":46,"lon":45},[49],{"name":50,"role":31,"phone":10,"phoneExt":10,"email":10},"Corneliu-Gheorge Popescu",{"facility":52,"status":38,"city":52,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"Eilenburg",{"type":43,"coordinates":54},[55,56],12.63338,51.45984,{"lat":56,"lon":55},[59],{"name":60,"role":31,"phone":10,"phoneExt":10,"email":10},"Johannes Schuster",{"facility":62,"status":38,"city":63,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":64,"geoPoint":68,"contacts":69},"Department of Angiology, University Hospital Leipzig,","Leipzig",{"type":43,"coordinates":65},[66,67],12.37129,51.33962,{"lat":67,"lon":66},[70],{"name":71,"role":31,"phone":10,"phoneExt":10,"email":10},"Andrej Schmidt",{"facility":73,"status":38,"city":74,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Elblandklinikum Radebeul","Radebeul",{"type":43,"coordinates":76},[77,78],13.66047,51.10654,{"lat":78,"lon":77},[81],{"name":82,"role":31,"phone":10,"phoneExt":10,"email":10},"Torsten Fuss",{"facility":73,"status":38,"city":84,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Riesa",{"type":43,"coordinates":86},[87,88],13.29168,51.30777,{"lat":88,"lon":87},[91],{"name":82,"role":31,"phone":10,"phoneExt":10,"email":10},{"facility":93,"status":38,"city":94,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":95,"geoPoint":99,"contacts":100},"REGIOMED Klinikum Sonneberg","Sonneberg",{"type":43,"coordinates":96},[97,98],11.17463,50.3592,{"lat":98,"lon":97},[101],{"name":102,"role":31,"phone":10,"phoneExt":10,"email":10},"Marcus Thieme",{"facility":104,"status":38,"city":105,"state":10,"zip":10,"country":40,"countryCode":41,"cosmosGeoPoint":106,"geoPoint":110,"contacts":111},"KKH Torgau","Torgau",{"type":43,"coordinates":107},[108,109],12.99617,51.56016,{"lat":109,"lon":108},[112],{"name":113,"role":31,"phone":10,"phoneExt":10,"email":10},"Lars Maiwald",{"type":115,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100392697","acotec-dcb-post-market-clinical-follow-up-100392697",false,"NCT04393389","Acotec DCB Post Market Clinical Follow-up","All Comers Post Market Clinical Follow-up to Continue the Surveillance of the Acotec Drug Coated PTA Catheter Orchid, Tulip and Litos in Lower Limb Treatment","FLOWER","Inclusion Criteria:\n\n* 1\\. Patient is ≥ 18 years old at the time of consent.\n* 2\\. Significant stenosis (≥70%) or occlusions of de-novo or restenotic lesion(s) located in iliac, superficial femoral, popliteal and\u002For infra-popliteal arteries suitable for angioplasty per operator visual assessment.\n* 3\\. Lesion(s) can be treated with available AcoArt Orchid (0.035\"), AcoArt Tulip (0.018\") and AcoArt Litos (0.014\") DCB device per current IFU.\n* 4\\. Subject has provided written informed consent prior to participation in the PMCF, understands the purpose of this PMCF and agrees to comply with all protocol-specified examinations and follow-up appointments.\n* 5\\. Rutherford Classification Category 2-6 Subjects with Rutherford Category 2 have gone through a conservative therapy without success.\n* 6\\. Inflow lesion treated prior to target lesion treatment\n\nExclusion Criteria:\n\n* 1\\. Rutherford Classification Category 0, 1\n* 2\\. Patient already enrolled in other investigational (interventional) studies that would interfere with study endpoints\n* 3\\. Inability to tolerate required antithrombotic or antiplatelet therapies.\n* 4\\. Non-dilatable severely calcified lesion.\n* 5\\. Known hypersensitivity\u002Fallergy to components of the investigational device\n* 6\\. Un-treated acute or subacute thrombus in the target lesion.\n* 7\\. Life expectancy \\\u003C 1 year.\n* 8\\. Pregnancy or female patient with child bearing potential not taking adequate contraceptives or currently lactating.\n* 9\\. Other comorbidities, which in the opinion of the investigator limit longevity or likelihood of compliance with protocol follow up.\n* 10\\. Myocardial infarction or stroke within 30 days prior to index procedure.","ALL","18 Years",{"count":127,"type":128},3000,"ESTIMATED","OBSERVATIONAL","All-comers, prospective, multi-center, single-arm, non-interventional post market clinical follow-up (PMCF) Cohort 1 - Claudicants: Rutherford Clinical Category (RCC) 2-3 Cohort 2 - Critical Limb Ischemia: Rutherford Clinical Category (RCC) 4-6",[132],"Peripheral Artery Disease","2024-07-30",{"date":135,"type":136},"2024-08-01","ACTUAL",{"date":138,"type":136},"2020-06-04",{"date":140,"type":128},"2027-03-01",{"name":5,"class":6},7]